

MEETING INVITATION

For Australian Healthcare Professionals only

GSK proudly invites you to the meeting

Optimising Treatment through Proactive Health Management



Time	Agenda

SPEAKERS



To register directly with your representative or for any questions regarding the meeting, please contact:



Three dark blue horizontal bars representing contact information fields.

Please scan the QR code to register now



Optimising Treatment through Proactive Health Management

COPD + ASTHMA LEARNING OBJECTIVES

Discuss differential diagnosis of COPD and asthma

Focus on the need for optimising treatment of patients with COPD and asthma currently on ICS/LABA

Understand the role of TRELEGY Ellipta, a Single Inhaler Triple Therapy in the management of moderate/severe COPD and asthma

SHINGLES LEARNING OBJECTIVES

Discuss the risk and impact of shingles

Recognise the importance of vaccinating adults ≥ 50 years of age

Describe the clinical profile of SHINGRIX

Develop strategies for implementing SHINGRIX discussions within your practice

Abbreviations: COPD: Chronic Obstructive Pulmonary Disease, ICS: Inhaled corticosteroid, LABA: Long acting beta₂ agonist, LAMA: Long acting muscarinic antagonist

TRELEGY ELLIPTA fluticasone furoate/umeclidinium/vilanterol

PBS Information: Severe asthma (200/62.5/25 mcg presentation only); Chronic obstructive pulmonary disease (100/62.5/25 mcg presentation only): Authority Required (streamlined). Criteria apply. Refer to PBS for full information.



SCAN QR CODE
to see full TRELEGY Ellipta Product Information

PLEASE REVIEW PRODUCT INFORMATION BEFORE PRESCRIBING.

Product Information can be accessed at www.gsk.com.au/trelegy

Indications: Maintenance treatment of adults with moderate to severe COPD who require LAMA+LABA+ICS (100/62.5/25 mcg presentation only). Not indicated for initiation in COPD. Maintenance treatment of asthma in adult patients who are not adequately controlled with an ICS+LABA. **Contraindications:** Severe milk-protein allergy or hypersensitivity to any of the ingredients. **Pregnancy:** Category B3. **Adverse Effects:** Nasopharyngitis, headache, cough, oropharyngeal pain, pneumonia, upper respiratory tract infection, viral respiratory tract infection, influenza, pharyngitis, dysphonia, rhinitis, arthralgia, back pain, constipation, sinusitis, bronchitis, urinary tract infection, candidiasis of mouth and throat.

Dosage: One inhalation once daily. After inhalation, rinse mouth with water without swallowing. Must be used regularly in asthma, even when asymptomatic.

SHINGRIX

Recombinant Varicella Zoster Virus glycoprotein E antigen (AS01_B adjuvanted vaccine)

PBS Information: This product is not listed on the PBS or the National Immunisation Program (NIP).



SCAN QR CODE
to see full SHINGRIX Product Information

PLEASE REVIEW PRODUCT INFORMATION BEFORE PRESCRIBING.

Product Information can be accessed at www.gsk.com.au/shingrix

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

Indication: SHINGRIX is indicated for the prevention of herpes zoster (HZ) and post-herpetic neuralgia in: adults 50 years of age or older, and in adults 18 years of age or older at increased risk of HZ. **Dosing and administration:** The primary vaccination schedule consists of two doses of 0.5 mL each; an initial dose followed by a second dose 2 to 6 months later. For subjects who are immunodeficient, immunosuppressed or likely to become immunosuppressed due to known disease or therapy, and who would benefit from a shorter vaccination schedule, the second dose can be given 1 to 2 months after the initial dose. SHINGRIX is for intramuscular injection only, preferably in the deltoid muscle. **Adverse Effects:** Very common ($\geq 10\%$) solicited local adverse reactions and solicited general adverse events were pain, redness, and swelling at the injection site; and myalgia, fatigue, headache, shivering, fever, and gastrointestinal symptoms, respectively.

This event is intended for registered Australian Healthcare Professionals only. Please contact your GSK Representative if you would like to extend this invitation to other registered Healthcare Professionals. This educational activity was initiated, developed and organised by GSK. This is an educational event for your professional development. Therefore, accompanying persons such as family members are not invited to attend. We, GlaxoSmithKline Australia Pty Ltd collect, use and disclose personal information about you so we can perform our business activities and functions. We collect your personal information in order to send you direct marketing material and to contact you regarding Optimising Treatment through Proactive Health Management. We may disclose your personal information to third parties we use in the ordinary operations of our business. If we do not collect your personal information, we may be unable to provide you with all of our services. Our privacy policy can be found at <http://au.gsk.com/en-au/privacy-policy> and contains information about how you may access and correct personal information held by us and how you can complain about a breach of privacy and how we will deal with such a complaint. If you require, you may access the information we hold about you by writing to the Privacy Officer, GlaxoSmithKline Australia Pty Ltd, Level 3, 436 Johnston Street, Abbotsford, 3067.

For information on GSK products or to report an adverse event involving a GSK product, please contact GSK Medical Information on 1800 033 109. GlaxoSmithKline Australia Pty Ltd. ABN 47 100 162 481. Melbourne, VIC. Trade marks are owned by or licensed to the GSK group of companies ©2023 GSK group of companies or its licensor.

PM-AU-SGX-LBND-230028 Date of approval: July 2023